HOME >> BIOLOGY >> NEWS
New data suggest anakinra may accelerate reduction in joint destruction and improve quality of life for rheumatoid arthritis patients

PHILADELPHIA, Pa., October 29, 2000 - Amgen (NASDAQ: AMGN) today announced that anakinra or interleukin-1 receptor antagonist (IL-1ra), an investigational rheumatoid arthritis (RA) therapy not yet approved by the U.S. Food and Drug Administration, may accelerate reduction in joint damage progression and improvement in the health-related quality of life for RA patients, according to results of several studies presented this week at the American College of Rheumatology (ACR) annual meeting.

Bone and Joint Data

In a double-blind, multicenter study, 472 patients were randomized to receive 30 mg, 75 mg or 150 mg daily treatment or placebo. After 6 months, the placebo patients were re-randomized to treatment with one of the anakinra doses. The patients were evaluated by radiographs using a modified Sharp assessment tool, which measures joint destruction based on erosive damage and joint space narrowing of the hand and wrist. The sum of these two subscales provides the total Sharp score. Increases in scores signify progressive structural destruction.

In the first analysis, patients treated with anakinra for a full year experienced an accelerated slowing of joint destruction in the second 6-month period relative to the significant improvements in the first 6 months of treatment. After six months, anakinra-treated patients experienced nearly twice the rate of reduction in joint destruction as the placebo group (increase in Sharp score of 1.86 vs. 3.61, respectively, p=0.002). After an additional six months of therapy, patients on anakinra experienced an increase of 1.18 compared with 1.32 in the placebo group (p<0.001). This accelerated improvement in benefit was seen at both 75 and 150 mg doses.

"Not only did patients on anakinra see benefits as early as six months on treatment, but the longer they were on therapy, the more improvement they experienced," said co-author Dr. Barry Bresnihan, professor of rheumatology, University Col
'"/>

Contact: Rebecca Hamm, Amgen
rhamm@amgen.com
805-447-3872
Porter Novelli
28-Sep-2000


Page: 1 2 3 4 5

Related biology news :

1. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
2. Research suggests new avenue for stopping, preventing colon cancer
3. New sign language suggests children create languages fundamentals through learning
4. Images of tail of protein needed for cell multiplication suggest anticancer drug targets
5. New research suggests early diet may play key role in protecting against childhood leukaemia
6. Serotonin metabolites in mollusks suggest pathways for human therapies
7. New research suggests link between maternal diet and childhood leukemia risk
8. Research suggests unborn children may be at risk from environmental pollution
9. Study suggests cell-cycle triggers might be cancer drug targets
10. Computer imaging of Archeopteryx skull suggests this dinosaur-bird link could fly
11. Study suggests humans can speed evolution

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2019)... ... 2019 , ... R3 Stem Cell is now offering its comprehensive Online ... code to use during checkout is FIFTYOFF and applies to both the one month ... regenerative therapies with over 12,000 successful stem cell procedures performed nationwide. A couple years ...
(Date:11/5/2019)... ... November 05, 2019 , ... Catalent, the ... biologics, gene therapies, and consumer health products, today announced it will present at ... Spain on Nov. 12 – 14, 2019. , On Wednesday, Nov. 13 at ...
(Date:10/30/2019)... ... 29, 2019 , ... LGC Maine Standards releases VALIDATE® UC1 ... 701sa & 704sa. The kits, in a human-urine matrix, evaluate CA, CL, CREA, ... kit, liquid, ready-to-use, and prepared using the CLSI EP06-A “equal delta” sample preparation, ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... Bode Technology ... of Forensic Genealogy, Melinde Lutz Byrne, to the organization. Byrne’s team will strengthen ... investigative leads to law enforcement through proven genealogy and DNA analysis methods. , ...
(Date:11/5/2019)... , ... November 04, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... cell line development technology, GPEx® Boost. The technology enhances Catalent’s proven GPEx ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 graph, a breakthrough knowledge ... drug360 brings tellic’s expertise in biomedical language processing and machine learning to bear ... between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts ...
(Date:10/29/2019)... ... October 29, 2019 , ... Researchers ... Using Silios CMS-C multispectral imagers , researchers identified people by the image ... based on retinal imaging, face recognition, fingerprints and vasculature. , The new ...
Breaking Biology Technology:
Cached News: